



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2013

Usefulness of IgM-specific enzyme immunoassays for serodiagnosis of syphilis: comparative evaluation of three different assays

Bosshard, Philipp P

Abstract: OBJECTIVES: IgM antibodies are usually the first to be produced during treponemal infection. Three commercially available enzyme immunoassays (EIA) for detection of IgM antibodies against *Treponema pallidum* were evaluated. METHODS: Results of the Anti-Treponema-pallidum-ELISA (IgM; Euroimmun), Pathozyne Syphilis M Capture (Omega Diagnostics) and recomWell Treponema IgM (Mikrogen) were compared with those of the T. pallidum particle agglutination (TPPA) and the Venereal Disease Research Laboratory (VDRL) tests for 307 serum samples. RESULTS: The overall sensitivity (95% confidence interval [CI]) of the TPPA was 100% (97.7-100%) compared to 83.3% (76.5-88.8%) of the VDRL, 88.5% (82.4-93.0%) of the Pathozyne, 84.6% (78.0-89.9) of the Euroimmun, and 73.6% (66.1-80.4%) of a modified recomWell test procedure. Specificities were in the range of 91.4-100%. In primary syphilis, sensitivities of the Pathozyne (89.8%; 95% CI, 79.2-96.2%) and Euroimmun tests (81.4%; 95% CI, 69.1-90.3%) were significantly higher ($p < 0.05$) than the sensitivity of the VDRL test (61%; 95% CI, 47.4-73.5%). IgM EIAs even were positive in some cases of suspected very early infection where the VDRL was non-reactive and the TPPA was indeterminate. CONCLUSIONS: In cases of suspected early infection specific IgM EIAs should be used in addition to other screening tests. The VDRL is not recommended for screening.

DOI: <https://doi.org/10.1016/j.jinf.2013.03.011>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-85204>

Journal Article

Accepted Version

Originally published at:

Bosshard, Philipp P (2013). Usefulness of IgM-specific enzyme immunoassays for serodiagnosis of syphilis: comparative evaluation of three different assays. *Journal of Infection*, 67(1):35-42.

DOI: <https://doi.org/10.1016/j.jinf.2013.03.011>

**Usefulness of IgM-specific enzyme immunoassays for serodiagnosis
of syphilis: comparative evaluation of three different assays**

Philipp P. Bosshard

Dept. of Dermatology, University Hospital Zurich, Zürich, Switzerland

Running title

Evaluation of three IgM-EIAs for diagnosis of syphilis

Corresponding author

Philipp P. Bosshard

Department of Dermatology

Zurich University Hospital

Gloriastrasse 31

CH - 8091 Zürich

Switzerland

Tel + 41 44 255 3972

Fax + 41 44 255 4418

philipp.bosshard@usz.ch

Keywords

Syphilis, serology, IgM, ELISA, EIA, diagnosis

Word count

Manuscript (excluding abstract, tables, acknowledgment and references): 2570

Summary

Objectives. IgM antibodies are usually the first to be produced during treponemal infection. Three commercially available enzyme immunoassays (EIA) for detection of IgM antibodies against *Treponema pallidum* were evaluated.

Methods. Results of the Anti-Treponema-pallidum-ELISA (IgM; Euroimmun), Pathozyme Syphilis-M Capture (Omega Diagnostics) and recomWell Treponema IgM (Mikrogen) were compared with those of the *Treponema pallidum* particle agglutination (TPPA) and the Venereal Disease Research Laboratory (VDRL) tests for 307 serum samples.

Results. The overall sensitivity (95% confidence interval [CI]) of the TPPA was 100% (97.7-100%) compared to 83.3% (76.5-88.8%) of the VDRL, 88.5% (82.4-93.0%) of the Pathozyme, 84.6% (78.0-89.9) of the Euroimmun, and 73.6% (66.1-80.4%) of a modified recomWell test procedure. Specificities were in the range of 91.4-100%. In primary syphilis, sensitivities of the Pathozyme (89.8%; 95% CI, 79.2-96.2%) and Euroimmun tests (81.4%; 95% CI, 69.1-90.3%) were significantly higher ($p < 0.05$) than the sensitivity of the VDRL test (61%; 95% CI, 47.4-73.5%). IgM EIAs even were positive in some cases of suspected very early infection where the VDRL was non-reactive and the TPPA was indeterminate.

Conclusions. In cases of suspected early infection specific IgM EIAs should be used in addition to other screening tests. The VDRL is not recommended for screening.

Keywords

Syphilis; serology; IgM; ELISA; EIA; diagnosis; *Treponema pallidum*

Introduction

Serology remains the mainstay of laboratory detection of *Treponema pallidum* infections. Two classes of antibody tests are available; treponemal and non-treponemal. In Europe, it is recommended to use a treponemal antigen test as a single screening test, e.g. an enzyme immunoassay (EIA) or the *Treponema pallidum* particle agglutination test (TPPA),¹ with positive samples being confirmed by a second treponemal test. Non-treponemal tests, e.g. VDRL (Venereal Disease Research Laboratory) or RPR (Rapid Plasma Reagin), are useful for detection of active infection and for monitoring treatment response,² however, they are less specific than treponemal tests and lack sensitivity in primary and late syphilis patients.²⁻⁵ Additionally, they are labour intensive and cannot be run on automated platforms.

IgM class antibodies are usually the first to be produced during treponemal infection.⁶ It has been shown that IgM-specific EIAs are very sensitive in detecting primary and secondary syphilis^{2,4,5,7-10} with the IgM EIA being the first test positive in some instances. It is recommended to request a specific anti-treponemal IgM test if primary syphilis is suspected.^{1,2} Although many different commercial IgM EIA tests are available, few have been analysed for their performance at different stages of syphilis, namely the Mercia Syphilis M EIA (Microgen Products Ltd)^{4,5,8-12} the Eti-syphilis-M (DiaSorin)⁷ and the recomWell Treponema IgM (Mikrogen).¹³ Additionally, the Mercia Syphilis M EIA has been evaluated for diagnosing maternal and congenital syphilis¹⁴ and the use of Euroimmun EIA and Western-blot IgG and IgM assays for screening blood donors has been investigated.¹⁵

In the present study, three commercially available EIAs to detect IgM antibodies to *T. pallidum* were evaluated (Anti-Treponema-pallidum-ELISA IgM, Euroimmun; Pathozyne Syphilis M Capture, Omega Diagnostics; recomWell Treponema IgM, Mikrogen). Sensitivities were determined with consecutive sera from untreated syphilis patients at different disease stages. Specificities were analysed by a panel of sera including sera of patients with diseases potentially interfering with syphilis serology tests.

79

80 **Material and Methods**

81 **Study design**

82 156 consecutive sera submitted to the syphilis serology laboratory at the Clinic of Dermatology,
83 University Hospital of Zurich of patients at the Zurich University Hospital which were diagnosed
84 between January 2008 and December 2010 having untreated syphilis were included in this
85 retrospective study.

86 Routine testing included the VDRL test (Dade Behring, Düringen, Germany), the TPPA
87 test (Fujirebio Inc., Tokyo, Japan), the Fluorescent Treponemal Antibody-Absorption test (FTA-
88 ABS, Biomérieux, Genève, Switzerland), and the Pathozyme Syphilis M Capture EIA (Omega
89 Diagnostic Ltd., Alva, United Kingdom). After routine testing, sera were stored at -20°C until
90 further testing in 2011 with the Anti-Treponema-pallidum-ELISA (IgM; Euroimmun, Lübeck,
91 Germany) and the recomWell Treponema IgM (Mikrogen, Neuried, Germany).

92 To assess the specificity, 151 sera were tested including sera known to be potentially
93 cross-reactive (anti-*Borrelia burgdorferi* IgM [$n = 10$], anti-Epstein-Barr virus IgM [$n = 10$], anti-
94 Cytomegalovirus IgM [$n = 10$], auto-immune disease (Lupus erythematosus) [$n = 1$], HIV
95 patients [$n = 20$] and pregnant women [$n = 20$]), negative sera without further specification ($n =$
96 50) and sera of previously treated syphilis patients ($n = 30$).

97

98 **Patient characteristics**

99 Based on clinical data obtained from patients charts and serological results, patients were
100 categorized as having primary syphilis ($n = 59$), secondary syphilis ($n = 66$), latent syphilis ($n =$
101 25), or tertiary syphilis ($n = 6$) (Table 1). 50/59 primary syphilis patients had typical ulcers at
102 ano-genital or oro-pharyngeal sites. The other nine patients had positive serology and
103 erythematous lesions on the penis or the tonsils ($n = 3$) or a possible exposition to syphilis
104 without clinic ($n = 6$). Secondary syphilis patients had muco-cutaneous skin lesions typical for
105 secondary syphilis. Patients with latent syphilis had positive serology but without clinical signs of

syphilis. Patients were classified as having tertiary syphilis based on a combination of clinical and serological findings as well as CSF analysis

Serological testing

All tests were performed according to the manufacturer's instructions. To avoid false-negative results due to the prozone phenomenon the VDRL was tested up to a 1:64 dilution.

The three EIAs are designed for the semi-quantitative detection of IgM antibodies against *T. pallidum*. The Euroimmun Anti-Treponema-pallidum-ELISA (IgM) and the recomWell Treponema IgM both involve indirect 'sandwich' EIA procedures using microtitration wells coated with the recombinant treponemal antigens Tp15, Tp17, Tp47 and TmpA. After incubation with the test serum, bound IgM antibodies are detected with an enzyme-labelled anti-human-IgM antibody. For the Euroimmun Anti-Treponema-pallidum-ELISA (IgM), prior to incubation with the test serum, interfering IgG antibodies are precipitated with anti-human-IgG antibodies. Results are calculated as index values (optical density of sample/cut-off value) and are then classified as negative (<0.8), equivocal (≥ 0.8 , <1.1) or positive (≥ 1.1).

According to the manufacturer's protocol for the recomWell a pre-adsorption of IgG antibodies must not be done. However, due to moderate performance all samples were also tested with a modified recomWell Treponema IgM protocol in which interfering IgG antibodies were precipitated with Gullsorb reagent (Meridian Bioscience, Ohio, United States) containing anti-human-IgG antibodies according to the manufacturer's protocol. For the recomWell Treponema IgM, results are calculated as antibody units per ml (optical density of sample/cut-off value $\times 20$) and are then classified as negative (<20), equivocal (≥ 20 , ≤ 24) or positive (>24).

In the Pathozyne Syphilis M Capture EIA microtitration wells are coated with anti-human IgM which captures IgM antibodies in the test serum onto the well. After washing a conjugate of native *T. pallidum* antigen (Tp15, Tp17, Tp44 and Tp47) labelled with horseradish peroxidase is applied. Results are calculated as index values (optical density of sample/cut-off value) and are then classified as negative (<0.9), equivocal (≥ 0.9 , ≤ 1.1) or positive (>1.1).

Equivocal results of any of the specific IgM EIAs were repeated and the second result was accepted as the final one. Thus, 27 positive sera and 5 control sera had to be repeated, i.e., 14 Euroimmun, 6 recomWell, and 12 Pathozyme tests. In 10, 12, and 10 cases, respectively, results became negative, became positive, or remained equivocal upon repetition. Repeated equivocal results were considered as positive for calculating sensitivity and specificity.

Statistical analysis

Confidence intervals were calculated with GraphPad Prism, Version 5.04 (GraphPad Software, Inc., La Jolla, California). Sensitivities were compared with the McNemar X^2 test¹⁶ online at <http://graphpad.com/QuickCalcs> (GraphPad Software, Inc., La Jolla, California last accessed 9th January 2013).

Results

Results of all tests are shown in Tables 2 and 3 and corresponding sensitivities and specificities are depicted in Table 4. In 148/156 patients the TPPA test was positive and in 8/156 it was equivocal/indeterminate. The VDRL test was positive or equivocal in 36/59 (61%) patients with primary syphilis, positive in 64/66 (97%) patients with secondary syphilis, in 24/25 (96%) patients with latent syphilis and in all six patients with tertiary syphilis. VDRL and TPPA titres were lower in primary syphilis compared to secondary, latent or tertiary syphilis (Table 2).

The IgM-specific EIAs started with low to moderate high scores in primary syphilis and had a peak in secondary and to a lesser extent in tertiary syphilis, while in latent syphilis the scores were lowest (Table 2). A total of 138 (88.5%), 100 (64.1), and 132 (84.6%) of 156 sera of syphilis patients were tested positive by the IgM-specific Pathozyme, recomWell, and Euroimmun tests, respectively (Tables 2 and 4). As the recomWell Treponema IgM initially showed moderate performance all specimens were retested with a modified protocol what

resulted in a significantly (McNemar $X^2 = 11.5$, $p < 0.001$) higher sensitivity (73.7% as opposed to 64.1%).

In primary syphilis (Table 4), the sensitivities (% sensitivity, 95% CI) of the Pathozyme (89.8%, 79.2-96.2%) and the Euroimmun test (81.4%, 69.1-90.3%) were significantly higher than the sensitivities of the VDRL (61%, 47.4-73.5%) and the modified recomWell test (62.7%, 49.2-75.0%) as assessed by the McNemar X^2 test ($X^2 > 3.841$, $p < 0.05$)¹⁶.

23/59 primary syphilis patients had a negative VDRL. These patients probably had early infection as the TPPA titres (median 1:320, interquartile range <1:80 – 1:320) were low, too. In this group, IgM-specific Pathozyme, modified recomWell, and Euroimmun tests were positive in 22/23, 10/23, and 17/23 cases, respectively. Detailed results of seven patients with indeterminate TPPA are summarized in Table 5; in all of them syphilis was confirmed with later control sera, i.e., TPPA became positive and IgM EIA tests decreased after therapy. It is therefore believed that they had very early infection. Pathozyme, modified recomWell, and Euroimmun tests were positive or equivocal in 7/7, 2/7 and 3/7 cases, respectively.

The specificity of all tests ranged from 91.4-100% (Tables 3 and 4). All investigated specific IgM tests showed some cross-reactivity, especially the Euroimmun Anti-Treponema-pallidum-ELISA had difficulties with sera containing IgM antibodies against human Herpes viruses (7/10 anti-Epstein-Barr virus IgM sera and 3/10 anti-Cytomegalovirus IgM sera).

Discussion

The clinical and laboratory diagnosis of primary syphilis can be difficult. Usually one or multiple, painless and indurate ulcers develop at the site of infection. However, the lesion may be atypical,^{1,17} e.g., i) only a papular lesion may develop, ii) it may be inconspicuous, iii) it does not develop in every case, iv) a syphilitic balanitis of Follman may be the only clinical expression. Patients might also seek medical advice after risk situations in the incubation period before development of clinical symptoms. Besides dark-field microscopy, which requires experienced

staff and is labour-intensive, and molecular tests, which are not yet generally used and are expensive, serological tests remain the most important tool for diagnosing syphilis. In the present study, and in those of others,^{4,5} the TPPA was the most sensitive single test in all stages of disease, confirming its suitability as a screening test.¹ The VDRL test sensitivity was only 61% for primary syphilis, which is similar to what we found previously (58%)² but somewhat lower than what other studies reported (66-87%).^{3,18,19} The sensitivity of the IgM-specific syphilis EIA assays for detecting primary syphilis was 89.8% for the Pathozyme Syphilis M Capture (Omega Diagnostics) test and 81.4% for the Anti-Treponema-pallidum-ELISA (IgM; Euroimmun). This was significantly higher than 62.7% of the modified recomWell Treponema IgM (Mikrogen) or 61% of the VDRL test. In secondary syphilis which corresponds to the hematogenic spreading of the pathogen throughout the entire body the EIAs had their highest sensitivities, whereas in latent syphilis which clinically is a silent period IgM EIA values were low and many samples were negative.

Most interestingly is the group of primary syphilis patients with negative VDRL. These 23/59 (39%) cases all would have been missed when the VDRL was used as the only first-line screening test as previously recommended in the United States.^{18,20} In this subgroup, the TPPA was positive in 17/23 and indeterminate in 6/23 cases. TPPA alone would have allowed diagnosing present or past syphilis infection in these cases (still, the six indeterminate cases would have been doubtful requiring confirmation with second samples). However, the combination of TPPA and IgM-specific EIA assays allowed correct diagnosis of early primary syphilis in 22/23 and 17/23 cases with the Pathozyme and the Euroimmun assay, respectively. The Pathozyme assay was even positive in seven cases with presumed very early infection with some patients eventually still being in the incubation phase (Table 5). It has been previously shown that a specific IgM EIA may be the only positive test in early infection.^{2,5} It is therefore suggested that in cases of suspected early infection specific IgM EIAs should be used in addition to other screening tests.¹ It is important that clinicians communicate the suspicion of early infection to the laboratory in order that an IgM EIA is utilized.

Most previous studies investigating IgM-specific commercial assays have examined the Mercia Syphilis M EIA (Microgen Products Ltd),^{4,5,8-12} in one study the Eti-syphilis-M was analysed (DiaSorin).⁷ The reported sensitivities are similar to the ones found here, for primary syphilis they were in the range of 82-94% and for secondary syphilis in the range of 60-100%. For latent syphilis the sensitivity was dependent on whether early (56-87%) or late (0-50%) latent cases were examined. In one previous study the recomWell Treponema IgM assay was investigated,¹³ the sensitivity in 19 primary syphilis cases was 89.5% which is higher than in the present work. However, the assay was negative in all samples of later stages of syphilis. Schmidt et al.¹⁰ evaluated nine commercially available EIAs with a panel of 52 highly selected sera from primary syphilis patients, all negative with the microhemagglutination test for *T. pallidum*. Eight assays were designed to detect IgG alone or in combination with IgM antibodies. Most interestingly, the one assay detecting only IgM antibodies (Mercia Syphilis M EIA) demonstrated the highest sensitivity (86.5%) as compared to the other tests (22.6-76.9%).

Remarkable is the fact that all these previous studies except two did not report the specificity. Ijsselmuiden et al.⁸ tested 48 samples of mainly treated syphilis patients and non-infected neonates with a specificity of 98% and Sambri et al.¹³ tested 200 samples from blood-donors and 60 samples from patients with possibly cross-reactive conditions (e.g. Lyme disease, mononucleosis, pregnancy) with 100% specificity. In the present study, 151 sera including 71 potentially cross-reactive samples were investigated for testing the specificity. Except for the Euroimmun assay which had some difficulties with sera which were positive for IgM antibodies against human Herpes viruses, all other assays showed specificities of 95.4-100%.

For monitoring the treatment response primarily non-treponemal tests such the VDRL or the RPR are recommended.^{1,3} It has been shown previously that specific IgM EIAs are a reliable supplement^{2,21,22} and this might be especially valuable in cases with an initially negative VDRL test (mainly primary syphilis cases) and in case of a slow decline or persisting low VDRL reactivity despite adequate therapy. However, it has to be noted that response rate may be different among different commercial IgM EIAs and also different as compared to the VDRL.

Studies which used the Mercia Syphilis M EIA reported negative test results one year after treatment in 92-100% of patients presenting with early syphilis^{21,22} - as compared to 62-87% in a study using the Pathozyme test.²

All three IgM tests are easy to perform and do not require special equipment or special skills and knowledge of the staff. They have total incubation times of 2-2.5 hours and can be executed routinely within half a day. The tests differ, however, in their accuracy with the recomWell being the least sensitive. The recomWell assay is an indirect 'sandwich' EIA. In this kind of assay patients IgG antibodies are usually precipitated with an anti-human IgG antibody to avoid a competition with IgM antibodies in binding to the recombinant antigens what can cause a false-negative result. This step is missing in the recomWell procedure. Therefore, a modified recomWell protocol precipitating interfering IgG antibodies was tested. The sensitivity thus significantly increased from 64.1 to 73.7%. This demonstrates that the pre-adsorption of interfering IgG antibodies increases the performance. With some optimization of the protocol the sensitivity might be increased even more.

A limitation of this study is the fact that the sera were stored at -20°C until testing with the Euroimmun and the recomWell assay. It cannot be entirely excluded that this might have influenced the result in some cases.

In summary, specific syphilis IgM EIA assays are highly sensitive in primary syphilis and are specific. It is suggested that in cases of suspected early infection specific IgM EIAs should be used in addition to other screening tests. Additionally, they allow differentiation of active and past infection and may be used as supplement for monitoring treatment response. EIAs from different manufacturers vary in their performance.

Addendum

During the course of this study Omega Diagnostics informed that the Pathozyme Syphilis M Capture test is suspended from production until further notice.

269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286

Conflict of interest

Mikrogen, Neuried, Germany and Pharma Consulting Marion Senn GmbH, Burgdorf, Switzerland sponsored 50% and 25% of costs of the recomWell Treponema IgM (Mikrogen) tests, respectively; Euroimmun Schweiz AG, Luzern, Switzerland has sponsored all Euroimmun Anti-Treponema-pallidum-ELISA (IgM) tests. The author has served as speaker for Euroimmun Switzerland and has received travel grants from Euroimmun Switzerland. No company had influence on the design of the study, interpretation of results, the final manuscript or any other part of the study.

Acknowledgments

I deeply appreciate the technical assistance of Tamara Eicher. I thank Thomas Kündig for critical review of the manuscript, Nicole Graf for statistical advice, and Walter Bossart and Reinhard Zbinden for providing potentially cross-reactive serum samples.

287 **References**

- 288 1. French P, Gomberg M, Janier M, Schmidt B, van Voorst Vader P, Young H. IUSTI: 2008
289 European guidelines on the management of syphilis. *Int J STD AIDS* 2009;**20**(5):300-9.
- 290 2. Fröhlich Knaute D, Graf N, Lautenschlager S, Weber R, Bosshard PP. Serological
291 response to treatment of syphilis according to disease stage and HIV status. *Clin Infect*
292 *Dis* 2012;**doi: 10.1093/cid/cis757**
- 293 3. Larsen SA, Steiner BM, Rudolph AH. Laboratory diagnosis and interpretation of tests for
294 syphilis. *Clin Microbiol Rev* 1995;**8**(1):1-21.
- 295 4. Manavi K, Young H, McMillan A. The sensitivity of syphilis assays in detecting different
296 stages of early syphilis. *Int J STD AIDS* 2006;**17**(11):768-71.
- 297 5. McMillan A, Young H. Qualitative and quantitative aspects of the serological diagnosis of
298 early syphilis. *Int J STD AIDS* 2008;**19**(9):620-4.
- 299 6. Shannon R, Booth SD. The pattern of immunological responses at various stages of
300 syphilis. *Br J Vener Dis* 1977;**53**(5):281-6.
- 301 7. Castro R, Prieto ES, Santo I, Azevedo J, Exposto Fda L. Evaluation of an enzyme
302 immunoassay technique for detection of antibodies against *Treponema pallidum*. *J Clin*
303 *Microbiol* 2003;**41**(1):250-3.
- 304 8. Ijsselmuiden OE, van der Sluis JJ, Mulder A, Stolz E, Bolton KP, van Eijk RV. An IgM
305 capture enzyme linked immunosorbent assay to detect IgM antibodies to treponemes in
306 patients with syphilis. *Genitourin Med* 1989;**65**(2):79-83.
- 307 9. Lefevre JC, Bertrand MA, Bauriaud R. Evaluation of the Captia enzyme immunoassays
308 for detection of immunoglobulins G and M to *Treponema pallidum* in syphilis. *J Clin*
309 *Microbiol* 1990;**28**(8):1704-7.
- 310 10. Schmidt BL, Edjlalipour M, Luger A. Comparative evaluation of nine different enzyme-
311 linked immunosorbent assays for determination of antibodies against *Treponema*
312 *pallidum* in patients with primary syphilis. *J Clin Microbiol* 2000;**38**(3):1279-82.
- 313 11. Young H, Pryde J, Duncan L, Dave J. The Architect Syphilis assay for antibodies to
314 *Treponema pallidum*: an automated screening assay with high sensitivity in primary
315 syphilis. *Sex Transm Infect* 2009;**85**(1):19-23.
- 316 12. Tabidze IL, Lee FK, Tambe P, Rocha E, Larsen SA, Stoll BJ, et al. Enzyme-linked
317 immunospot assay for the diagnosis of active *Treponema pallidum* infection during the
318 various stages of syphilis. *Sex Transm Dis* 1999;**26**(8):426-30.
- 319 13. Sambri V, Marangoni A, Simone MA, D'Antuono A, Negosanti M, Cevenini R. Evaluation
320 of recomWell Treponema, a novel recombinant antigen-based enzyme-linked
321 immunosorbent assay for the diagnosis of syphilis. *Clin Microbiol Infect* 2001;**7**(4):200-5.
- 322 14. Rawstron SA, Mehta S, Bromberg K. Evaluation of a *Treponema pallidum*-specific IgM
323 enzyme immunoassay and *Treponema pallidum* western blot antibody detection in the
324 diagnosis of maternal and congenital syphilis. *Sex Transm Dis* 2004;**31**(2):123-6.
- 325 15. Wang LN, Li JM. Evaluation of immunoglobulin M and G Western blot and ELISA for
326 screening antibodies to *Treponema pallidum* in blood donors. *Sex Transm Dis*
327 2009;**36**(7):413-6.
- 328 16. Linnet K, Bossuyt PM, Moons KG, Reitsma JB. Quantifying the accuracy of a diagnostic
329 test or marker. *Clin Chem* 2012;**58**(9):1292-301.
- 330 17. Tramont EC. *Treponema pallidum* (Syphilis). In: Mandell GL, Bennett JE, Dolin R,
331 editors. *Principles and practice of infectious diseases*. 6th ed. Philadelphia: Elsevier,
332 2005:2768-85.
- 333 18. Creegan L, Bauer HM, Samuel MC, Klausner J, Liska S, Bolan G. An evaluation of the
334 relative sensitivities of the venereal disease research laboratory test and the *Treponema*
335 *pallidum* particle agglutination test among patients diagnosed with primary syphilis. *Sex*
336 *Transm Dis* 2007;**34**(12):1016-8.
- 337 19. Janier M, Chastang C, Spindler E, Strazzi S, Rabian C, Marcelli A, et al. A prospective
338 study of the influence of HIV status on the seroreversion of serological tests for syphilis.
339 *Dermatology* 1999;**198**(4):362-9.

- 340 20. Sena AC, White BL, Sparling PF. Novel *Treponema pallidum* serologic tests: a paradigm
341 shift in syphilis screening for the 21st century. *Clin Infect Dis* 2010;**51**(6):700-8.
- 342 21. McMillan A, Young H. Reactivity in the Venereal Diseases Research Laboratory test and
343 the Mercia IgM enzyme immunoassay after treatment of early syphilis. *Int J STD AIDS*
344 2008;**19**(10):689-93.
- 345 22. Rotty J, Anderson D, Garcia M, Diaz J, Van de Waarsenburg S, Howard T, et al.
346 Preliminary assessment of *Treponema pallidum*-specific IgM antibody detection and a
347 new rapid point-of-care assay for the diagnosis of syphilis in human immunodeficiency
348 virus-1-infected patients. *Int J STD AIDS* 2010;**21**(11):758-64.
- 349
- 350